We are delighted to have advised Vaccine Manufacturing and Innovation Centre Limited on their sale to Catalent, Inc.
Vaccine Manufacturing and Innovation Centre Limited (‘VMIC’) is a private limited company, limited by guarantee and the facility is located on the highly prestigious Harwell Science and Innovation campus near Oxford.
The organisation was created to lead vaccine manufacturing innovation in the UK. The board of VMIC and the Government decided to divest the part-built facility as it was no longer deemed strategic and wished to secure future employment for the current workforce (approximately 60-FTE’s), as well as a long-term strategic partnership with an appropriate buyer from a suitable geography.
We ran a focussed process with a number of leading potential buyers, pushing to complete in an agreed timeframe whilst maximising the return received by VMIC.
Our lead, tax and restructuring advisory teams worked seamlessly together to guide and advise VMIC’s management through the complexities of the disposal and preparations for the subsequent members voluntary liquidation.
Our lead advisory team provided significant hands-on support to the financial team, both in collating forecasts and due diligence They drove significant value increases to the transaction whilst managing multiple stakeholder groups to achieve an outstanding result.
Grant Thornton have been a real driving force in this process, helping support and balance the needs of multiple stakeholders whilst maximising the deal value. I really appreciate just how hard you have all worked in order to achieve this, and it has been an absolute pleasure to work alongside you.Neil Jones CEO, Vaccine Manufacturing and Innovation Centre Limited